Congestive Heart Failure News and Research

RSS

Congestive Heart Failure is a condition in which the heart can't pump blood the way it should. In some cases, the heart can't fill with enough blood. In other cases, the heart can't send blood to the rest of the body with enough force. Some people have both problems. "Heart failure" doesn't mean that your heart has stopped or is about to stop working. However, it's a serious condition that requires medical care. Heart failure develops over time as the pumping of the heart grows weaker. It can affect the right side of the heart only or both the left and right sides of the heart. Most cases involve both sides of the heart.

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Millennium: The Takeda Oncology Company today announced data examining the use of VELCADE in the treatment of patients with relapsed or refractory light chain (AL) amyloidosis. Amyloidosis is a rare condition in which excessive proteins build up in organs or tissues, such as the heart, kidney or liver. These data were presented at the Annual Meeting of the American Society of Clinical Oncology (ASCO) held in Chicago, Illinois, June 4-8, 2010.

5 Jun 2010

Heart attack patients treated beyond maximum recommended time have increased mortality: Study

An examination of the treatment received by patients with myocardial infarction (heart attack) at 80 hospitals in Quebec indicates that those who received either primary percutaneous coronary intervention (PPCI; such as angioplasty) or fibrinolysis (administration of medication to dissolve blood clots) beyond the times recommended in international guidelines had a significantly increased risk of death within 30 days, along with an increased risk of the combined outcome of death or readmission for heart attack or heart failure at one year, according to a study in the June 2 issue of JAMA.

2 Jun 2010

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

CoaguSense™, Inc., a diagnostic device company that has been in stealth mode for the past two years, today unveiled the first portable point-of-care Prothrombin Time/International Normalized Ratio (PT/INR) analyzer to directly detect blood clotting time for patients stabilized on oral anti-coagulation medications such as Coumadin® or warfarin.

2 Jun 2010

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Bioheart, Inc., announced today plans for establishing two Centers of Excellence in the Middle East to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease. Dr. Karl E. Groth, Chairman and CEO, and Peggy A. Farley, Chief Operating and Financial Officer, are now in that region holding discussions and performing site inspections.

29 May 2010

Patients Medical offers innovative stroke treatments to live longer, healthier life

Patients Medical, a leading integrative medical center in New York City, offers innovative stroke treatments such as hyperbaric oxygen therapy, acupuncture, diet therapy and customized intravenous nutrition drips. Daniel Silverstein, MD, holistic physician, recommends focusing on prevention to avoid a stroke and to live a longer, healthier life.

29 May 2010

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Pfizer Oncology will present new data highlighting the company's focused approach to cancer drug development through the identification and validation of molecular targets. These results will be presented at the 46th Annual American Society of Clinical Oncology meeting in Chicago from June 4-8.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Response Biomedical Corporation today announced that it has been granted a Class 3 (near patient/point-of-care) Medical Device license by Health Canada to market its RAMP® Respiratory Syncytial Virus (RSV) Assay in Canada.

18 May 2010

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Aastrom Biosciences, Inc., the leading developer of autologous cellular therapies for the treatment of severe cardiovascular diseases, today announced that the first patient has been treated in the company's U.S. Phase 2 catheter-based clinical trial to treat dilated cardiomyopathy (DCM). Treatment was performed by interventional cardiologist Timothy D. Henry, M.D., FACC, at the Minneapolis Heart Institute® at Abbott Northwestern Hospital in Minneapolis, MN.

17 May 2010

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

Long-term, regular use of vitamin E in women 45 years of age and older may help decrease the risk of chronic obstructive pulmonary disease by about 10 percent in both smokers and non-smokers, according to a study conducted by researchers at Cornell University and Brigham and Women's Hospital.

17 May 2010

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

Geron Corporation today reported positive preclinical study data showing that GRNCM1, Geron's cardiomyocyte product derived from human embryonic stem cells, does not cause cardiac arrhythmias after transplantation into a model of chronic heart damage designed to test this potential safety concern.

14 May 2010

St. Jude Medical launches Promote Quadra CRT-D in Europe

St. Jude Medical, Inc., a global medical device company, today announced the European launch of its Promote Quadra™ cardiac resynchronization therapy defibrillator (CRT-D). The Promote Quadra CRT-D is the industry's first quadripolar pacing system, which offers physicians the ability to more effectively and efficiently manage the ever-changing pacing needs of patients with heart failure.

12 May 2010

HHS announces $16M award for Geisinger to create Keystone Beacon Community

Today the Department of Health and Human Services announced that Geisinger Health System will receive $16 million to create the Keystone Beacon Community as part of HHS's Beacon Community cooperative program.

5 May 2010

Response Biomedical first-quarter total revenue down 43%

Response Biomedical Corporation today announced financial results for the first quarter ended March 31, 2010.

4 May 2010

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Studies and analyses of the Crohn’s Disease (CD) treatment Cimzia® (certolizumab pegol) demonstrating new data will be exhibited at Digestive Disease Week (DDW) 2010, taking place in New Orleans from May 1-5, 2010.

30 Apr 2010

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended March 31, 2010. For the first quarter of 2010, the Company reported a net loss of $8.6 million, or $0.19 per share compared with a net loss of $19.7 million, or $0.51 per share, for the same period in 2009.

29 Apr 2010

Researchers take major step to predict adverse drug reactions using genetic information

In a new study, researchers at Mount Sinai School of Medicine have taken a major step toward the ability to predict adverse drug reactions, using genetic, cellular, and clinical information to learn why some medicines cause heart arrhythmias in patients. Published in the April 20 issue of the journal Science Signaling, the new framework described in the study could potentially be applied to the study of medications that treat other diseases and disorders such as epilepsy and autism.

23 Apr 2010

Research associates diabetes with atrial fibrillation

As the U.S. population keeps aging and gaining weight, diabetes is becoming increasingly common. Some research has associated diabetes with the most common kind of chronically irregular heartbeat, called atrial fibrillation, which can raise the risk for stroke and death. But results of past studies of diabetes and atrial fibrillation have conflicted.

23 Apr 2010

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Genentech, Inc., a wholly owned member of the Roche Group, announced today that the company submitted a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Herceptin® (trastuzumab) plus chemotherapy in people with advanced, HER2-positive adenocarcinoma of the stomach, including gastroesophageal junction cancer.

23 Apr 2010

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Pfizer Inc. announced today the discontinuation of the SUN 1170 Phase 3 open-label study of Sutent(r) (sunitinib malate) in advanced hepatocellular carcinoma, or liver cancer. Following a review by the independent Data Monitoring Committee, the study was discontinued based on a higher incidence of serious adverse events in the sunitinib arm compared to the sorafenib arm and the fact that sunitinib did not meet the criteria to demonstrate that it was either superior or non-inferior to sorafenib in the survival of patients with advanced hepatocellular cancer.

23 Apr 2010

Congestive Heart Failure News and Research

Millennium announces data on VELCADE in treatment of patients with amyloidosis

Heart attack patients treated beyond maximum recommended time have increased mortality: Study

CoaguSense unveils first portable point-of-care PT/INR Monitoring System for patients on oral anticoagulants

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Patients Medical offers innovative stroke treatments to live longer, healthier life

New data highlighting Pfizer's approach to cancer drug development to be presented at ASCO meeting

Genentech to present new data for targeted cancer medicines at 46th ASCO

Health Canada grants Response Biomedical Class 3 Medical Device license for RAMP RSV Assay

Aastrom Biosciences initiates treatment in Phase 2 catheter-based clinical trial for dilated cardiomyopathy

Long-term, regular use of vitamin E in women may help decrease risk of COPD: Study

GRNCM1 do not cause cardiac arrhythmias after transplantation: Preclinical study

St. Jude Medical launches Promote Quadra CRT-D in Europe

HHS announces $16M award for Geisinger to create Keystone Beacon Community

Response Biomedical first-quarter total revenue down 43%

New data on Cimzia for Crohn’s Disease treatment to be demonstrated at DDW 2010

Neurocrine Biosciences reports net loss of $8.6M in first quarter 2010

Researchers take major step to predict adverse drug reactions using genetic information

Research associates diabetes with atrial fibrillation

Genentech submits sBLA for Herceptin plus chemotherapy for advanced HER2-positive stomach cancer

Pfizer announces discontinuation of SUN 1170 Phase 3 study of Sutent in HCC

Industry Focus eBook - Analytical Chemistry (2nd Edition) eBook

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News